Pan-Modification Antibodies and Antibody-Conjugated Beads for PTM Proteomics: Mechanisms, Research Methods, and ANTBIO Solutions

Post-translational modifications (PTMs) diversify protein function without changing the underlying sequence, and their dysregulation is a recurring theme in cell signalling, metabolism and disease. Two experimental bottlenecks dominate the field: detecting a change in global modification level, and locating the exact modified residues behind it. This article describes how pan-modification antibodies and antibody-conjugated agarose beads address these two bottlenecks in sequence — Western blot screening first, affinity enrichment and mass spectrometry second — and summarises the ANTBIO reagent portfolio that supports the workflow.

1. What Are Pan-Modification Antibodies?

A pan-modification antibody recognises a chemical modification on an amino acid residue regardless of the protein carrying it. Instead of reporting one target protein, it reports the aggregate modification state of a sample: a single Western blot lane integrates thousands of substrate proteins and shows whether a treatment, a genotype or a disease state shifts the modification level up or down. Because the same reagent can be used across cell lines and tissues, pan-modification antibodies function as a first-pass sensor — a molecular “smoke detector” for a modification class — before any site-level experiment is designed.

2. Why Screening Comes Before Mapping

• Not every change is worth mapping: enrichment and LC-MS/MS are expensive in sample, instrument time and analysis; a Western blot on the same lysates answers that question before any enrichment is attempted.
• Modification stoichiometry is usually low: modified peptides are a minor fraction of the digest, so a global readout is the only way to judge whether enrichment is likely to succeed.
• Different modification classes behave differently: lysine acylations such as lactylation, acetylation, crotonylation, succinylation, malonylation and butyrylation are structurally distinct and require class-specific reagents; ubiquitin and ubiquitin-like modifiers (K-ε-GG, K-ε-GV, SUMO-1) require their own antibodies because the epitope is a remnant peptide, not a small chemical group.
• Cross-reactivity is the main failure mode: an anti-acetyllysine antibody that also binds crotonyl- or succinyl-lysine will report a false change. Specificity has to be demonstrated against other acyl-peptides and unmodified peptides, not assumed.

3. Major Classes of PTMs Addressed by the Portfolio

3.1 Lysine acylations

L- and D-lactylation, acetylation, propionylation (Kpr, the most recent addition), crotonylation, succinylation, malonylation, butyrylation, 2-hydroxyisobutyrylation, β-hydroxybutyrylation, methacryloylation, fumarylation and pyruvylation. These share the lysine ε-amino group as the attachment site, which is precisely why antibody specificity has to be validated against neighbouring acyl groups.

3.2 Ubiquitin and ubiquitin-like modifiers

K-ε-GG (ubiquitin remnant), K-ε-GV (UFM1) and SUMO-1. Here the recognised epitope is the diglycine or related remnant left after tryptic digestion, or the modifier protein itself, so these reagents are used for immunoprecipitation and immunoaffinity purification as well as for blotting.

3.3 Phosphorylation, methylation and glycosylation

Phosphotyrosine, phospho-Ser/Thr, phosphothreonine and phospho-motif antibodies (Akt substrates RXXS/T and RXRXXS/T, PKA substrate RRXS/T); pan tri-methyllysine and symmetric dimethylarginine; O-GlcNAc; and tyrosine or Ser/Thr sulfation.

3.4 Less common and exclusively available modifications

Hypusine, AMPylation, D-lactylation and pyruvylation are among the modification types that ANTBIO lists as exclusively available, and they extend the same screening logic to modification classes that are difficult to cover with commercial catalogues.

4. Core Methods: From Blot to Modified Site

4.1 Global screening by Western blot

1. Lyse samples under conditions that preserve the modification (include deacetylase and deubiquitinase inhibitors where the modification is labile).
2. Quantify, resolve by SDS-PAGE and transfer; load equal protein amounts so that lane intensity reflects modification level rather than loading.
3. Probe with the pan-modification antibody, then with a loading control; keep exposure times identical across lanes and blots being compared.
4. Use the supplied ready-to-use buffer system — the reagents are formulated for immediate use, so the screening step does not require in-house buffer preparation.

4.2 Enrichment of modified peptides with antibody-conjugated agarose beads

1. Digest the lysate (trypsin) and desalt; the modification must remain intact on the peptide.
2. Resuspend the beads — they are supplied ready-to-use, with the antibody already conjugated, so no in-house coupling step is needed.
3. Incubate digest with beads, then pellet by centrifugation and wash to remove non-specifically bound peptides; the low non-specific adsorption is what keeps the background of the subsequent run low.
4. Elute the bound modified peptides and proceed to LC-MS/MS; the eluate is a simplification of the original digest, not a different sample.

4.3 LC-MS/MS acquisition and readout

Enriched peptides are sequenced by data-independent acquisition; the number of modified sites identified is the practical measure of enrichment performance. On a Thermo Astral platform with a 24-minute DIA method, 293T cell samples enriched with the L-lactylation beads identified more than 10,000 modified sites; the characterised performance of the two bead products is 10,000+ sites for L-lactylation (S0F0016) and 20,000+ sites for K-ε-GG (S0F0018) in cell samples.

5. ANTBIO Solutions for PTM Research

ANTBIO supplies the two reagent classes as one workflow, summarised here by category; catalogue numbers are listed in the tables below.

• Pan-modification antibodies (20+ modification types): recombinant rabbit monoclonal platform (S-RMabMix™), covering the common acylations, ubiquitin and ubiquitin-like modifiers, phosphorylation, methylation, O-GlcNAc and sulfation.
• Exclusive modification types: AMPylation, pyruvylation, D-lactylation and hypusine, plus the recently launched propionylation (Kpr) antibody.
• Antibody-conjugated agarose beads: premium series built on selected monoclonal antibody mixes and a classic series, covering lactylation, acetylation, succinylation, ubiquitin, 2-hydroxyisobutyrylation, phosphotyrosine, O-GlcNAc, UFM1, fumarylation and SDMA.
• Validated specificity: each pan-modification antibody is tested by ELISA binding and dot blot; the antibodies recognise the corresponding modified peptide and show no cross-reactivity with other acylated peptides or unmodified peptides.

Pan-modification antibodies

Antibody-conjugated agarose beads

6. Future Trends

PTM proteomics is moving from cataloguing modification types to resolving them at single-site resolution in low-input and clinical samples. Two consequences follow for reagents: enrichment beads have to keep non-specific binding low enough for short DIA gradients, and antibody specificity has to be documented against the full set of chemically related modifications rather than a single negative control. Bead coverage for the less common acylations — propionylation, crotonylation, 2-hydroxyisobutyrylation and the sulfation classes among them — is the area where the portfolio is still expanding, and where the screening-to-enrichment workflow currently ends at the antibody step.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.